血脂康对不稳定型心绞痛患者血浆hs-CRP和MMP-9水平的影响  

Effect of Xuezhikang on Plasma High Sensitivity C-Reactive Protein and the Level of Matrix Metalloproteinase-9 in Patients with Unstable Angina Pectoris

作　　者：刘丽军[1] 赵秀峰[1] 马燕霞[1] 信栓力[1] 常超[1] 宋敏[1] 王艳[1] 南静[1] 李书香 刘镜 

机构地区：[1]邯郸市第一医院心内科,河北邯郸056002 [2]邯郸市峰峰矿区中医院外科,河北邯郸056200 [3]冀中能源邯郸矿业集团聚隆矿业有限公司医务室,河北邯郸056305

出　　处：《临床误诊误治》2012年第12期73-75,共3页Clinical Misdiagnosis & Mistherapy

基　　金：河北省医学科学研究重点课题计划(07150)

摘　　要：目的探讨血脂康对不稳定型心绞痛(UAP)患者血浆超敏C反应蛋白(hs-CRP)及基质金属蛋白酶-9(MMP-9)水平的影响。方法本研究104例均经冠状动脉造影明确诊断,其中40例正常(对照组),64例为UAP(UAP组)。UAP组予药物洗脱1周并常规予抗凝、血管紧张素转化酶抑制剂、β-受体阻滞剂、扩血管药等,并加服血脂康0.6 g/d,疗程4周。对照组及UAP组于入院第1天及服药4周后分别检测血浆hs-CRP及MMP-9水平并进行比较。结果治疗前UAP组血浆hs-CRP、MMP-9分别为(24.13±6.24)ng/L、(19.75±4.63)mg/L,对照组分别为(18.97±5.87)ng/L、(15.45±4.38)mg/L,差异有统计学意义(P<0.01);服用血脂康4周后UAP组血浆hs-CRP及MMP-9分别为(18.78±5.97)ng/L、(13.28±4.77)mg/L,与治疗前比较差异有统计学意义(P<0.01);与对照组比较差异无统计学意义(P>0.05)。结论血脂康可显著降低UAP患者血浆hs-CRP及MMP-9水平,对改善UAP患者的预后有一定作用。Objective To investigate the effect of Xuezhikang on plasma high sensitive C-reactive protein（hsCRP） and matrix metalloproteinase-9（MMP-9） in patients with unstable angina pectoris（UAP）.Methods 104 patients were diagnosed by coronary arteriongraphy,among whom,40 healthy people were regarded as control group and 64 patients with UAP as UAP group.Patients in UAP group were treated with medical elution for 1 week,routine anticoagulation,angiotensin-converting enzyme inhibitor,β acceptor blocking agent,dilated hemal drugs and oral Xuezhikang（0.6 g/d） for 4 weeks.Plasma hsCRP and the levels of MMP-9 were detected and compared between control group on the 1st day upon admission and UAP group 4 weeks after oral administration.Results The levels of plasma hsCRP and MMP-9 before treatment in UAP group were（24.13±6.24） ng/L and（19.75±4.63） mg/L,and of（18.97±5.87） ng/L and（15.45±4.38） mg/L in control group and the differences were statistically significant（P0.01）.Plasma hsCRP and MMP-9 before treatment and 4 weeks after Xuezhikang-administration were（18.78±5.97） ng/L and（13.28±4.77） mg/L respectively（P0.01）,and the differences were statistically significant（P0.01）;but there was no significant difference compared with control group（P0.05）.Conclusion Xuezhikang has a beneficial effect on decreasing plasma hsCRP and the level of MMP-9,and may improve prognosis of patients.

关 键 词：血脂康 心绞痛 不稳定型 超敏C反应蛋白 基质金属蛋白酶-9 

分 类 号：R259[医药卫生—中西医结合]